Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Opugotamig Biologics Sequence Review Report 2026: Folate receptor alpha Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Opugotamig, an antibody targeting Folate receptor alpha.
Read →
Latest Hotspot
8 min read
Lanerkitug Biologics Sequence Review Report 2026: CCR8 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lanerkitug, an antibody targeting CCR8.
Read →
Latest Hotspot
8 min read
Mipletamig Biologics Sequence Review Report 2026: IL3RA × CD3E Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mipletamig, an antibody targeting IL3RA × CD3E.
Read →
Latest Hotspot
8 min read
Precemtabart Biologics Sequence Review Report 2026: CEACAM5 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Precemtabart, an antibody targeting CEACAM5.
Read →
Latest Hotspot
8 min read
Ragistomig Biologics Sequence Review Report 2026: PD-L1 × 4-1BB Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ragistomig, an antibody targeting PD-L1 × 4-1BB.
Read →
Latest Hotspot
8 min read
Lumistobart Biologics Sequence Review Report 2026: SIRPA Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lumistobart, an antibody targeting SIRPA.
Read →
8 min read
Lancastotug Biologics Sequence Review Report 2026: TIGIT Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lancastotug, an antibody targeting TIGIT.
Read →
8 min read
Luvagrobart Biologics Sequence Review Report 2026: NGF Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Luvagrobart, an antibody targeting NGF.
Read →
Latest Hotspot
8 min read
Givastomig Biologics Sequence Review Report 2026: Claudin 18.2 × 4-1BB Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Givastomig, an antibody targeting Claudin 18.2 × 4-1BB.
Read →
Latest Hotspot
8 min read
Etakafusp Biologics Sequence Review Report 2026: CD8 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etakafusp, an antibody targeting CD8.
Read →
Latest Hotspot
8 min read
Izastobart Biologics Sequence Review Report 2026: C5AR1 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Izastobart, an antibody targeting C5AR1.
Read →
Latest Hotspot
8 min read
Calotatug Biologics Sequence Review Report 2026: HER2 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Calotatug, an antibody targeting HER2.
Read →
<
1
<<
346
347
348
349
350
>>
1420
>